US20100094003A1 - Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases - Google Patents

Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases Download PDF

Info

Publication number
US20100094003A1
US20100094003A1 US12/653,319 US65331909A US2010094003A1 US 20100094003 A1 US20100094003 A1 US 20100094003A1 US 65331909 A US65331909 A US 65331909A US 2010094003 A1 US2010094003 A1 US 2010094003A1
Authority
US
United States
Prior art keywords
formula
compound
hydroxy
nmr
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/653,319
Inventor
Gary Brian Evans
Peter Charles Tyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/653,319 priority Critical patent/US20100094003A1/en
Publication of US20100094003A1 publication Critical patent/US20100094003A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to a process for the preparation of certain nucleoside analogues.
  • the invention relates to a process that includes the reaction of formaldehyde, or a formaldehyde equivalent, with a cyclic amine and a heteroaromatic compound to give methylene linked cyclic amine deazapurines.
  • Nucleoside analogues that are potent inhibitors of purine nucleoside phosphorylase (PNP) and purine phosphoribosyltransferases (PPRT) are useful in treating parasitic infections, T-cell malignancies, autoimmune diseases and inflammatory disorders ⁇ see e.g. V. L. Schramm, Biochimica et Biophysica Acta, 1587 (2002) 107-117 ⁇ .
  • the analogues are also useful for immunosupression in organ transplantation.
  • nucleoside analogues that are potent inhibitors of 5′-methylthioadenosine phosphorylase (MTAP) and 5′-methylthioadenosine nucleosidase (MTAN) are useful:
  • nucleoside analogues that are potent inhibitors of the aforementioned nucleoside phosphorylases and nucleosidases
  • the applicants have also discovered a new class of compounds that are potent inhibitors of these nucleoside phosphorylases and hydrolases (PCT Patent Application PCT/NZ03/00186, “inhibitors of Nucleoside Phosphorylases and Nucleosidases”).
  • the Mannich reaction is a condensation reaction between three components, namely an amine, formaldehyde and a compound with an active hydrogen atom such as a heteroaromatic compound e.g. indole (pages 812-814, Vogel's Textbook of Practical Organic Chemistry, 4 th Edition, revised by B. S. Fumiss, A. J. Hannaford, V. Rogers, P. W. G. Smith and A. R. Tatchell, Longmans, London, 1978).
  • a heteroaromatic compound e.g. indole
  • Mannich reactions have been used to assemble compounds that incorporate a 9-deazapurine moiety linked via a methylene group to aliphatic and alicyclic amines [G. A. Modnikova et al., “Pyrrolo[3,2-d]pyrimidines. III. 7-Aminomethyl-substituted pyrrolo[3,2-d]pyrimidines”, Khim.-farm. Zh., 1983, 352-356 (English translation)].
  • Compounds that incorporate a pyrimidine moiety linked via a methylene group to a cyclic secondary amine have also been assembled using Mannich reactions. [V. V. Filichev and E. B. Pedersen, “Synthesis of 1′-aza-C-nucleosides from (3R,4R)-4-(hydroxymethyl)pyrrolidin-3-ol”, Tetrahedron, 57 (2001) 9163-9168].
  • the invention provides process for preparing a compound of the formula (I)
  • Z is hydrogen, halogen, hydroxy, SQ or OQ, where Q is an optionally substituted alkyl, aralkyl or aryl group. It is also preferred that A is CH. It is further preferred that Y is H.
  • W is NR 1
  • V is CH 2 and X is CH 2 .
  • R 1 is a radical of formula (II) as defined in claim 1 , where A is CH and E is N.
  • D is H or NH 2 .
  • B is NH 2 , OH or Cl.
  • Preferred processes of the invention include those where Z in the compound of formula (I) is methanesulfonate, p-toluenesulfonate or trifluoromethanesulfonate. Most preferably Z is methanesulfonate.
  • Preferred processes of the invention also include those where the compounds of formula (III) and (IV) are reacted with formaldehyde. Alternatively it is preferred that the compounds of formula (III) and (IV) are reacted with a formaldehyde equivalent such as paraformaldehyde.
  • the invention also provides compound of formula (I) when prepared by a process according to claim 1 .
  • the invention provides a process for preparing a compound of formula (I) as defined in claim 1 including:
  • the invention provides a process for preparing a compound of formula (I) as defined in claim 1 including:
  • the invention provides a process of preparing a compound of formula (I) as defined in claim 1 including:
  • the present invention provides a useful synthetic route to compounds that are potential inhibitors of PNP, PPRT, MTAN, MTAP and/or nucleoside hydrolases (NH). Such compounds may find use in the treatment of parasitic infections, T-cell malignancies, autoimmune diseases and inflammatory disorders. These compounds may also be used as antimicrobial agents, as antitumour agents, or as agents for treating parasitic infections.
  • sulfonate leaving group means an alkyl or aryl sulfonate such as methanesulfonate or benzenesulfonate, or a substituted form thereof such as bromobenzenesulfonate, trifluoromethanesulfonate or p-toluenesulfonate.
  • protecting group means a group that selectively protects an organic functional group, temporarily masking the chemistry of that functional group and allowing other sites in the molecule to be manipulated without affecting the functional group. Suitable protecting groups are known to those skilled in the art and are described, for example, in Protective Groups in Organic Synthesis (3 rd Ed.), T. W. Greene and P. G. M. Wuts, John Wiley & Sons Inc (1999).
  • Compounds of formula (IV) defined above may be prepared by known methods.
  • processes for the preparation of the compounds 3H,5H-pyrrolo[3,2-d]pyrimidin-4-one (9-deazahypoxanthine) and 2-amino-3H,5H-pyrrolo[3,2-d]pyrimidin-4-one (9-deazaguanine), compounds 1 and 2 shown below are described in PCT Patent Application PCT/NZ00/00048, “Process for Preparing Inhibitors of Nucleoside Metabolism and Substrates” and in R. H. Fumeaux and P. C. Tyler, J. Org. Chem., 64 (1999) 8411-8412.
  • 9-deazaadenine (3) can be prepared by treatment of 9-deazahypoxanthine (1) with POCl 3 and then with ethanolic ammonia.
  • (3R,4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidine hydrochloride (5) (154 mg, 1.0 mmol) and sodium acetate (82 mg, 1.0 mmol) were dissolved in water (2 mL) and to the solution were added aqueous formaldehyde (82 ⁇ L, 1.0 mmol) and 9-deazaguanine (Furneaux and Tyler, J. Org. Chem., 1999, 64, 8411-8412) (120 mg, 0.8 mmol). The reaction was stirred at 95° C. for 12 h.
  • Residual impurities (9-deazahypoxanthine) could be removed by column chromatography on silica eluting with CH 2 Cl 2 :MeOH:NH 4 OH (8:1.8:0.2 v/v/v) to give 28 in 36% yield.
  • the present invention provides a useful synthetic route to compounds that are inhibitors of PNP, PPRT, MTAN, MTAP and/or NH.
  • the compounds may be useful in the treatment of diseases in which the inhibition of PNP, PPRT, MTAN, MTAP and/or NH is desirable.
  • diseases include cancer, bacterial infection, protozoal infection or T-cell mediated diseases.

Abstract

The present invention relates to a new process for the preparation of compounds of general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine nucleosidases (MTAN) and/or nucleoside hydrolases (NH). The present invention relates to a new process for the preparation of compounds of general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine nucleosidases (MTAN) and/or nucleoside hydrolases (NH).

Description

    TECHNICAL FIELD
  • This invention relates to a process for the preparation of certain nucleoside analogues. In particular, the invention relates to a process that includes the reaction of formaldehyde, or a formaldehyde equivalent, with a cyclic amine and a heteroaromatic compound to give methylene linked cyclic amine deazapurines.
    • BACKGROUND
  • Nucleoside analogues that are potent inhibitors of purine nucleoside phosphorylase (PNP) and purine phosphoribosyltransferases (PPRT) are useful in treating parasitic infections, T-cell malignancies, autoimmune diseases and inflammatory disorders {see e.g. V. L. Schramm, Biochimica et Biophysica Acta, 1587 (2002) 107-117}. The analogues are also useful for immunosupression in organ transplantation.
  • Related nucleoside analogues that are potent inhibitors of 5′-methylthioadenosine phosphorylase (MTAP) and 5′-methylthioadenosine nucleosidase (MTAN) are useful:
  • (a) as anti-microbial compounds, and in decreasing the virulence of microbial infections by decreasing production of the quorum sensing pathway;
  • (b) as agents for treating parasitic infections such as malaria that infects red blood cells {see e.g. G. A. Kicska et al., J. Biol. Chem., 277 (2002) 3226-3231}; and
  • (c) as anti-tumour compounds, potentially in combination therapy with methotrexate or azaserine.
  • The applicants have previously disclosed potent inhibitors of such enzymes in a class called the Immucillins, based upon deazapurines covalently linked directly to aza-sugar moieties (U.S. Pat. Nos. 5,985,848 and 6,066,722, “Inhibitors of Nucleoside Metabolism”; and WO 02/19371, “Nucleoside Metabolism Inhibitors”).
  • In the search for new and improved nucleoside analogues that are potent inhibitors of the aforementioned nucleoside phosphorylases and nucleosidases, the applicants have also discovered a new class of compounds that are potent inhibitors of these nucleoside phosphorylases and hydrolases (PCT Patent Application PCT/NZ03/00186, “inhibitors of Nucleoside Phosphorylases and Nucleosidases”).
  • The preparation of such nucleoside analogues is by way of multi-step chemical syntheses. Consequently, the time and cost required for each synthesis can be considerable. There is therefore a need for more efficient and cost effective methods of preparing compounds in this new class.
  • The Mannich reaction is a condensation reaction between three components, namely an amine, formaldehyde and a compound with an active hydrogen atom such as a heteroaromatic compound e.g. indole (pages 812-814, Vogel's Textbook of Practical Organic Chemistry, 4th Edition, revised by B. S. Fumiss, A. J. Hannaford, V. Rogers, P. W. G. Smith and A. R. Tatchell, Longmans, London, 1978).
  • Mannich reactions have been used to assemble compounds that incorporate a 9-deazapurine moiety linked via a methylene group to aliphatic and alicyclic amines [G. A. Modnikova et al., “Pyrrolo[3,2-d]pyrimidines. III. 7-Aminomethyl-substituted pyrrolo[3,2-d]pyrimidines”, Khim.-farm. Zh., 1983, 352-356 (English translation)]. Compounds that incorporate a pyrimidine moiety linked via a methylene group to a cyclic secondary amine have also been assembled using Mannich reactions. [V. V. Filichev and E. B. Pedersen, “Synthesis of 1′-aza-C-nucleosides from (3R,4R)-4-(hydroxymethyl)pyrrolidin-3-ol”, Tetrahedron, 57 (2001) 9163-9168].
  • The applicants have now found that a Mannich reaction can be used to prepare compounds that incorporate a 9-deazapurine or an 8-aza-9-deazapurine moiety (or their 2-aza-analogues) linked via a methylene group to a cyclic secondary amine. These compounds are described as potent inhibitors, or potentially potent inhibitors, of nucleoside phosphorylases and nucleosidases in PCT Patent Application PCT/NZ03/00186.
  • It is therefore an object of the present invention to provide a process for preparing these compounds, or at least to provide a useful choice.
    • STATEMENTS OF INVENTION
  • In a first aspect, the invention provides process for preparing a compound of the formula (I)
  • Figure US20100094003A1-20100415-C00001
      • wherein:
      • V is selected from CH2 and NH, and W is NR1; or
      • V is NR1, and W is selected from CH2 and NH;
      • X is selected from CH2 and CHOH in the R or S-configuration, except where W is selected from NH and NR1, then X is CH2;
      • Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH and NR1, then Y is hydrogen;
      • Z is selected from hydrogen, halogen, hydroxy, a sulfonate leaving group, SQ, OQ and Q, where Q is an optionally substituted alkyl, aralkyl or aryl group; and
      • R1 is a radical of the formula (II)
  • Figure US20100094003A1-20100415-C00002
      • wherein:
      • A is selected from N, CH and CR2, where R2 is selected from halogen, optionally substituted alkyl, aralkyl or aryl, OH, NH2, NHR3, NR3R4 and SR5, where R3, R4 and R5 are each optionally substituted alkyl, aralkyl or aryl groups;
      • B is selected from OH, NH2, NHR6, SH, hydrogen and halogen, where R6 is an optionally substituted alkyl, aralkyl or aryl group;
      • D is selected from OH, NH2, NHR7, hydrogen, halogen and SCH3, where R7 is an optionally substituted alkyl, aralkyl or aryl group; and
      • E is selected from N and CH;
      • including reacting a compound of the formula (III)
  • Figure US20100094003A1-20100415-C00003
      • wherein:
      • V is selected from CH2 and NH, and W is NH; or
      • V is NH, and W is selected from CH2 and NH;
      • X is selected from CH2 and CHOH in the R or S-configuration, except where W is NH, then X is CH2;
      • Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH, then Y is hydrogen; and
      • Z is selected from hydrogen, halogen, hydroxy, a sulfonate leaving group, SQ, OQ and Q, where Q is an optionally substituted alkyl, aralkyl or aryl group;
      • with a compound of the formula (IV)
  • Figure US20100094003A1-20100415-C00004
      • wherein A, B, D, and E are as defined above;
      • and with formaldehyde or a formaldehyde equivalent.
  • Preferably, Z is hydrogen, halogen, hydroxy, SQ or OQ, where Q is an optionally substituted alkyl, aralkyl or aryl group. It is also preferred that A is CH. It is further preferred that Y is H.
  • Preferably W is NR1, V is CH2 and X is CH2. It is also preferred that R1 is a radical of formula (II) as defined in claim 1, where A is CH and E is N.
  • It is further preferred that D is H or NH2. Additionally, it is preferred that B is NH2, OH or Cl.
  • Preferred processes of the invention include those where Z in the compound of formula (I) is methanesulfonate, p-toluenesulfonate or trifluoromethanesulfonate. Most preferably Z is methanesulfonate.
  • Preferred processes of the invention also include those where the compounds of formula (III) and (IV) are reacted with formaldehyde. Alternatively it is preferred that the compounds of formula (III) and (IV) are reacted with a formaldehyde equivalent such as paraformaldehyde.
  • The more preferred processes of the invention include those where the compound of formula (I) is:
      • (3R,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-hydroxymethyl-pyrrolidine;
      • (3R,4R)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
      • (3R,4S)-4-(benzylthiomethyl)1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine;
      • (3R,4S)-4-(4-chlorophenylthiomethyl)1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine;
      • (3R,4R)-1-[(6-chloro-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine
      • (3R,4R)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-4-(methanesulfonyl)-pyrrolidine;
      • (3R,4S)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
      • (3R,4S)-4-(ethylthiomethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine;
      • (3R,4S)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-4-(propylthiomethyl)-pyrrolidine;
      • (3R,4S)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-4-(isopropylthiomethyl)-pyrrolidine;
      • (3R,4S)-4-(butylthiomethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine;
      • (3R,4S)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-4-(phenylthiomethyl)-pyrrolidine;
      • (3R,4S)-1-[(9-deaza-adenin-9-yl)methyl]-4-(4-fluorophenylthiomethyl)-3-hydroxy-pyrrolidine;
      • (3R,4S)-4-(3-chlorophenylthiomethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine;
      • (3R,4S)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-4-(cyclohexylthiomethyl)pyrrolidine;
      • (3R,4S)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-4-(4-pyridylthiomethyl)-pyrrolidine;
      • (3R,4R)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-4-(methoxymethyl)-pyrrolidine;
      • (3R,4R)-4-(benzyloxymethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine;
      • (3R,4R)-1-[(9-deazaguanin-9-yl)methyl]-3-hydroxy-4-hydroxymethyl-pyrrolidine;
      • (3R,4S)-1-[(9-deazahypoxanthin-9-yl]-3-hydroxy-4-(propylthiomethyl)-pyrrolidine;
      • (3R,4S)-4-(butylthiomethyl)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-pyrrolidine;
      • (3R,4S)-1-[(9-deaza-6-chloro-purin-9-yl)methyl]-3-hydroxy-4-(2-phenylethyl)pyrrolidine;
      • (3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-propyl-pyrrolidine;
      • (3R,4S)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-propyl-pyrrolidine; or
      • (3R,4S)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine.
  • The invention also provides compound of formula (I) when prepared by a process according to claim 1.
  • In one embodiment, the invention provides a process for preparing a compound of formula (I) as defined in claim 1 including:
      • (i) reacting a compound of formula (III) as defined in claim 1 with a compound of formula (IV) as defined in claim 1 and with formaldehyde or a formaldehyde equivalent, where any one or more of V, W, X, Y and Z of the compound of formula (III) is protected with a suitable protecting group; and
      • (ii) removing the one or more protecting groups to give the compound of formula (I).
  • In another embodiment, the invention provides a process for preparing a compound of formula (I) as defined in claim 1 including:
      • (i) reacting a compound of formula (III) as defined in claim 1 with a compound of formula (IV) as defined in claim 1 and with formaldehyde or a formaldehyde equivalent, where any one or more of A, B, D and E of the compound of formula (IV) is protected with a suitable protecting group; and
      • (ii) removing the one or more protecting groups to give the compound of formula (I).
  • In still another embodiment, the invention provides a process of preparing a compound of formula (I) as defined in claim 1 including:
      • (i) reacting a compound of formula (III) as defined in claim 1 with a compound of formula (IV) as defined in claim 1 and with formaldehyde or a formaldehyde equivalent, where any one or more of V, W, X, Y and Z of the compound of formula (III) is protected with a suitable protecting group and where any one or more of A, B, D and E of the compound of formula (IV) is protected with a suitable protecting group; and
      • (ii) removing the one or more protecting groups to give the compound of formula (I).
    DETAILED DESCRIPTION
  • The present invention provides a useful synthetic route to compounds that are potential inhibitors of PNP, PPRT, MTAN, MTAP and/or nucleoside hydrolases (NH). Such compounds may find use in the treatment of parasitic infections, T-cell malignancies, autoimmune diseases and inflammatory disorders. These compounds may also be used as antimicrobial agents, as antitumour agents, or as agents for treating parasitic infections.
  • Previous synthetic routes to compounds of formula (I) have been time-consuming and costly. In contrast, the present synthesis is a facile route to this useful class of compounds. The synthetic procedure involves using a Mannich reaction to couple a 9-deazapurine or an 8-aza-9-deazapurine moiety (or their 2-aza-analogues) to a cyclic secondary amine.
  • The applicants have therefore found that the desired compounds of formula (I) are advantageously prepared in good yield in a one-step synthesis.
  • It will be appreciated that the representation of a compound of formula (I), where B and/or D is a hydroxy group, is of the enol-type tautomeric form of a corresponding amide, and this will largely exist in the amide form. The use of the enol-type tautomeric representation is simply to allow fewer structural formulae to represent the compounds of the invention.
  • Similarly, it will be appreciated that the representation of a compound of formula (I), where B and/or D is a thiol group, is of the thioenol-type tautomeric form of a corresponding thioamide, and this will largely exist in the thioamide form. The use of the thioenol-type tautomeric representation is simply to allow fewer structural formulae to represent the compounds of the invention.
  • As used herein, the term “sulfonate leaving group” means an alkyl or aryl sulfonate such as methanesulfonate or benzenesulfonate, or a substituted form thereof such as bromobenzenesulfonate, trifluoromethanesulfonate or p-toluenesulfonate.
  • As used herein, the term “protecting group” means a group that selectively protects an organic functional group, temporarily masking the chemistry of that functional group and allowing other sites in the molecule to be manipulated without affecting the functional group. Suitable protecting groups are known to those skilled in the art and are described, for example, in Protective Groups in Organic Synthesis (3rd Ed.), T. W. Greene and P. G. M. Wuts, John Wiley & Sons Inc (1999).
  • Compounds of the formula (III) defined above may be prepared by known methods, as described in PCT Patent Application PCT/NZ03/00186 and the references cited therein. Procedures for the preparation of selected compounds of formula (III) are described herein.
  • Compounds of formula (IV) defined above may be prepared by known methods. In particular, processes for the preparation of the compounds 3H,5H-pyrrolo[3,2-d]pyrimidin-4-one (9-deazahypoxanthine) and 2-amino-3H,5H-pyrrolo[3,2-d]pyrimidin-4-one (9-deazaguanine), compounds 1 and 2 shown below, are described in PCT Patent Application PCT/NZ00/00048, “Process for Preparing Inhibitors of Nucleoside Metabolism and Substrates” and in R. H. Fumeaux and P. C. Tyler, J. Org. Chem., 64 (1999) 8411-8412. Further, 9-deazaadenine (3) can be prepared by treatment of 9-deazahypoxanthine (1) with POCl3 and then with ethanolic ammonia.
  • Figure US20100094003A1-20100415-C00005
  • One advantage of the applicants' new process is that neither the amine nor the heterocyclic component needs to have protecting groups on the functional groups that are not directly involved in the reaction chemistry. Nevertheless, there may be occasions where it is advantageous to utilize a protected form of a compound of formula (III) and/or formula (IV) as components in the reaction.
  • Suitably protected forms of compounds of formula (III) are described in U.S. Pat. Nos. 5,985,848 and 6,066,722, “Inhibitors of Nucleoside Metabolism” and WO 02/19371, “Nucleoside Metabolism Inhibitors”. It is essential that suitably protected forms of compounds of the formula (IV) have a proton at position-9 of the 9-deazapurine or 8-aza-9-deazapurine moiety (or their 2-aza-analogues).
  • Suitably protected forms of compounds of formula (IV) are described in PCT Patent Application PCT/NZ03/00186, “Inhibitors of Nucleoside Phosphorylases and Nucleosidases”. It is essential that protected forms of compounds of the formula (III) have an unprotected ring amino-group.
    • Examples
  • The following examples further illustrate the invention. It is to be appreciated that the invention is not limited to the examples.
    • Example 1 Mannich Reaction—General Procedure
  • Figure US20100094003A1-20100415-C00006
  • General procedure for the preparation of compounds of formula (3) using the Mannich reaction shown in Scheme 1; Pyrrolidine hydrochlorides of formula (1) (1.0 mol equiv.; as listed in Table 1 as “Amine reactant” unless otherwise specified) and sodium acetate (1.0 mol. equiv.) were dissolved in water and 1,4-dioxane (4:1 v/v, 2 mL per mmol) and to the solution were added aqueous formaldehyde (1.0-1.5 mol. equiv.) and the substituted 9-deazapurine of formula (2) (0.8-1.5 mol equiv.). The reaction was stirred at the temperature and for the time shown in Table 1. Silica gel (1.0 g per mmol of 1) was added and the mixture was evaporated to dryness. Purification by chromatography on silica gel, using gradient elution with CH2Cl2: MeOH: NH4OH (95:5:1→80:20:1 v/v/v) as the eluent, afforded the compound of formula (3) as detailed in Table 1 as the free base or partial acetic acid salt, which was converted to the HCl salt by addition and evaporation of excess conc. HCl [Evans, G. B.; Fumeaux, R. H.; Tyler, P. C.; Schramm, V. L. Org. Lett. 2003, 5, 3639-3640.] The preparations of the pyrrolidine hydrochlorides of formula (1) are exemplified in the Preparative Examples.
  • TABLE 1
    Compounds Prepared via the Mannich Reaction General
    Procedure
    Reaction
    Amine Time Substituents Yield
    Cpd No. Temp (° C.) reactant (h) R1 R2 R3 R4 (%)
    4 95 5 16 OH OH OH H 47
    6 95 5 1 OH OH NH2 H 65
    7 95 41 1 SBn OH NH2 H 72
    8 95 39 1 SPh-p-Cl OH NH2 H 72
    9 95 5 3 OH OH Cl H 78
    10 90 53 1 OSO2Me OH NH2 H 39
    11 95 32 1 SMe OH NH2 H 39
    12 85 33 2 SEt OH NH2 H 60
    13 90 34 3 S-n-Pr OH NH2 H 59
    14 95 35 3 S-iso-Pr OH NH2 H 38
    15 90 36 3 SBu OH NH2 H 52
    16 95 37 1 SPh OH NH2 H 57
    17 90 38 1 SPh-p-F OH NH2 H 27
    18 90 40 1.5 SPh-m-Cl OH NH2 H 52
    19 95 44 3 SChx OH NH2 H 34
    20 85 45 2 S-4-pyridyl OH NH2 H 45
    21 85 42 1.5 OMe OH NH2 H 59
    22 90 43 1.5 OBn OH NH2 H 22
    23 95 5 12 OH OH OH NH2 57
    24 90 34 3 SPr OH OH H 78
    25 90 36 3 SBu OH OH H 72
    26 95 49 12 C-Bn OH Cl H 38
    27 95 52 2.5 C-Et OH NH2 H 31
    28 95 52 5 C-Et OH OH H 36
    • Example 1.01
  • (3R,4R)-1-[(9-Deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-hydroxymethyl-pyrrolidine (4). Starting with 9-deazahypoxanthine (Fumeaux and Tyler, J. Org. Chem., 1999, 64, 8411-8412) and (3R,4R)-3-hydroxy-4-hydroxymethyl-pyrrolidine hydrochloride (5) (Evans et al, J. Med. Chem., 2003, 46 5271-5276), the Mannich reaction general procedure (above) was followed to afford compound 4 as the acetic acid salt. After conversion to the HCl salt and 1H and 13C NMR spectra analysis, the compound was found to be identical in all respects with that previously reported (Evans et a.l J. Med. Chem. 2003, 46, 5271-5276).
    • Example 1.02
  • (3R,4R)-1-[(9-Deaza-adenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine (6). Starting with 9-deaza-adenine (Preparative Example 3.01) and (3R,4R)-3-hydroxy-4-hydroxymethyl-pyrrolidine (5), the Mannich reaction general procedure (above) was followed to afford compound 6 as the acetic acid salt. 1H NMR (d4-MeOH) δ 8.20 (s, 1H), 7.65 (s, 1H), 4.27 (s, 1H), 4.22 (quintet, J=3.0 Hz, 1H), 3.59 (m, 2H), 3.46 (dd, J=11.1, 8.3 Hz, 1H), 3.26 (dd, J=11.4, 5.7 Hz, 1H), 3.11 (dd, J=11.4, 3.0 Hz, 1H), 2.95 (dd, J=11.2, 6.8 Hz, 1H), 2.37 (brs, 1H), 1.82 (s, 3H). 13C NMR (d4-MeOH) 152.9, 151.9, 147.1, 132.0, 115.8, 108.2, 73.6, 63.1, 61.9, 56.0, 50.8, 49.5, 23.7. HRMS (MH+) calc for C12H18N5O2: 264.1461. Found 264.1457.
    • Example 1.03
  • (3R,4S)-4-(Benzylthlomethyl)1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolldine (7). The Mannich reaction general procedure (above) was followed to afford compound 7 as the acetic acid salt. The acetic acid salt was converted to the free base via ion exchange chromatography. 1H NMR (d4-MeOH) 8.17 (s, 1H), 7.46 (s, 1H), 7.26-7.16 (m, 5H), 3.93-3.90 (m, 1H), 3.83-3.74 (m, 2H), 3.68 (s, 2H), 3.03-2.97 (m, 1H), 2.80 (dd, J=10.2, 6.4 Hz, 1H), 2.66-2.58 (m, 2H), 2.38 (dd, J=12.5, 8.9 Hz, 1H), 2.30 (dd, J=9.5, 7.2 Hz, 1H), 2.20-2.14 (m, 1H). 13C NMR (d4-MeOH) 152.5, 151.4, 147.4, 140.4, 130.4, 130.4, 129.8, 115.5, 112.9, 77.3, 62.7, 59.2, 49.3, 48.6, 37.5, 35.6. HRMS (MH+) calc for C19H24N5OS: 370.1702. Found 370.1694.
    • Example 1.04
  • (3R,4S)-4-(4-Chlorophenylthlomethyl)1-[(9-deaza-adenin-9-yl]methyl-3-hydroxy-pyrrolidine (8). The Mannich reaction general procedure (above) was followed to afford compound 8 as the acetic acid salt. 1H NMR (d4-MeOH) 8.25 (s, 1H), 7.84 (s, 1H), 7.35-7.23 (m, 5H), 4.54 (s, 2H), 4.30 (m, 1H), 3.74 (dd, J=11.9, 7.9 Hz, 1H), 3.59 (dd, J=12.2, 5.6 Hz, 1H), 3.40-3.15 (m, 4H), 2.89 (dd, J=13.5, 9.1 Hz, 1H), 2.47 (brs, 1H), 1.98 (s, 3H). 13C NMR (d4-MeOH) 153.0, 151.8, 146.1, 135.7, 134.0, 133.2, 132.2, 130.7, 115.7, 105.5, 74.6, 60.4, 57.3, 49.2, 47.7, 36.1, 23.0. HRMS (MH+) calc for C18H21CIN5OS: 390.1155. Found 390.1264.
    • Example 1.05
  • (3R,4R)-1-[(6-Chloro-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine (9). Starting with 6-chloro-9-deazapurine (K. Imai, Chem. Pharm. Bull., 1964, 12, 1030) and (3R,4R)-3-hydroxy-4-hydroxymethyl-pyrrolidine, the Mannich reaction general procedure (above) was followed to afford compound 9 as the acetic acid salt. 1H NMR (D2O) 8.34 (s, 1H), 7.98 (s, 1H), 4.48 (s, 2H), 4.31 (m, 1H), 3.68 (dd, J=12.1, 8.3 Hz, 1H), 3.53 (d, J=5.9 Hz, 2H), 3.45 (dd, J=12.6, 5.5 Hz, 1H), 3.32 (dd, J=12.6, 2.5 Hz, 1H), 3.13 (dd, J=12.0, 7.4 Hz, 1H), 2.40 (brs, 1H), 1.82 (s, 3H). 13C NMR (d4-MeOH) 149.7, 148.6, 143.4, 137.6, 124.8, 104.5, 71.3, 60.7, 59.8, 54.4, 48.0, 47.8, 23.5. HRMS (MH+) calc for C12H16CIN4O2: 283.0962. Found 283.0973.
    • Example 1.06
  • (3R,4R)-1-[(9-Deaza-adenin-9-yl)methyl]-3-hydroxy-4-(methanesulfonyl)-pyrrolidine (10). The Mannich reaction general procedure (above) was followed to afford compound 10. 1‘H NMR (d 4-MeOH) 8.17 (s, 1H), 7.52 (s, 1H), 4.30-3.82 (m, 5H), 3.10-3.00 (m, 1H), 3.06 (s, 3H), 2.94 (dd, J=10.3, 6.3 Hz, 1H), 2.71 (dd, J=10.3, 4.1 Hz, 1H), 2.53 (dd, J=10.1, 6.7 Hz, 1H), 2.43-2.34 (m, 1H). 13C NMR (d4-MeOH) 152.6, 151.5, 147.2, 130.7, 115.6, 112.0, 73.8, 71.8, 62.4, 56.0, 49.4, 49.1, 37.5.
    • Example 1.07
  • (3R,4S)-1-[(9-Deaza-adenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine (11). The Mannich reaction general procedure (above) was followed to afford compound 11 as the acetic acid salt. After conversion to the HCl salt and 1H and 13C NMR spectra analysis, the compound was found to be identical in all respects with that previously reported. (Evans et al., J. Med. Chem. 2003, 46, 5271-5276).
    • Example 1.08
  • (3R,4S)-4-(Ethylthiomethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine (12). The Mannich reaction general procedure (above) was followed to afford compound 12. 1H NMR (d4-MeOH) 8.16 (s, 1H), 7.52 (s, 1H), 4.00-3.82 (m, 3H), 3.12 (dd, J=9.9, 7.9 Hz, 1H), 2.92 (dd, J=10.5, 6.3 Hz, 1H), 2.76-2.68 (m, 2H), 2.55-2.41 (m, 4H), 2.25-2.15 (m, 1H), 1.21 (t, J=7.4 Hz, 3H). 13C NMR (d4-MeOH) 152.5, 151.5, 147.3, 130.7, 115.6, 112.1, 77.0, 62.4, 59.1, 49.4, 48.8, 35.5, 27.2, 15.5. HRMS (MH+) calc for C14H22N5OS: 308.1540. Found 308.1535.
    • Example 1.09
  • (3R,4S)-1-[(9-Deaza-adenin-9-yl)methyl]-3-hydroxy-4-(propylthiomethyl)-pyrrolidine (13). The Mannich reaction general procedure (above) was followed to afford compound 13. 1H NMR (d4-MeOH) 8.17 (s, 1H), 7.50 (s, 1H), 4.00-3.79 (m, 3H), 3.08 (dd, J=9.8, 7.9 Hz, 1H), 2.86 (dd, J=10.3, 6.4 Hz, 1H), 2.72-2.62 (m, 2H), 2.50-2.38 (m, 4H), 2.22-2.12 (m, 1H), 1.55 (sextet, J=7.3 Hz, 2H), 0.95 (t, J=7.3 Hz, 3H). 13C NMR (d4-MeOH) 152.5, 151.4, 147.4, 130.5, 115.6, 112.7, 77.2, 62.6, 59.2, 49.4, 49.0, 36.1, 35.6, 24.3, 14.1. HRMS (MH+) calc for C15H24N5OS: 322.1696. Found 322.1709.
    • Example 1.10
  • (3R,4S)-1-[(9-Deaza-adenin-9-yl)methyl]-3-hydroxy-4-(isopropylthiomethyl)-pyrrolidine (14). A variation of the Mannich reaction general procedure (above) using 20% 1,4-dioxane in water as the solvent and 0.9 mol equiv. of 9-deazaadenine afforded the crude title compound 14 (386 mg, 80%) after column chromatography on silica eluting with CH2Cl2:MeOH:NH4OH (8:1.8:0.2). Residual impurities could be removed by column chromatography on silica eluting with CH2Cl2:NH3(7N) in MeOH to afford title compound 14 (183 mg, 38%). 1H NMR (MeOH-d4): δ ppm: 8.16 (s, 1H), 7.49 (s, 1H), 3.99-3.94 (m, 1H), 3.82 (dd, J=18.7, 13.4 Hz, 1H), 3.04 (dd, J=9.7, 7.9 Hz, 1H), 2.95-2.82 (m, 2H), 2.75 (dd, J=12.5, 6.0 Hz, 1H), 2.66 (dd, J=10.3, 4.2 Hz, 1H), 2.50 (dd, J=12.5, 9.1 Hz, 1H), 2.38 (dd, J=9.7, 7.1 Hz, 1H), 2.21-2.10 (m, 1H), 1.23, 1.22 (2s, 3H each). 13C NMR (MeOH-d4): δ ppm: 152.48, 151.38, 147.40, 130.45, 115.54, 112.90, 77.29, 62.66, 59.26, 49.32, 49.09, 36.49, 34.66, 24.19.
    • Example 1.11
  • (3R,4S)-4-(Butylthiomethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine (15). The Mannich reaction general procedure (above) was followed to afford compound 15. 1H NMR (d4-MeOH) 8.16 (s, 1H), 7.50 (s, 1H), 3.99-3.79 (m, 3H), 3.08 (dd, J=9.7, 7.9 Hz, 1H), 2.87 (dd, J=10.3, 6.4 Hz, 1H), 2.75-2.69 (m, 2H), 2.51-2.38 (m, 4H), 2.22-2.12 (m, 1H), 1.55-1.32 (m, 4H), 0.90 (t, J=7.3 Hz, 3H). 13C NMR (d4-MeOH) 152.5, 151.4, 147.4, 130.5, 115.6, 112.6, 77.1, 62.6, 59.2, 49.4, 49.0, 36.1, 33.3, 33.2, 23.3, 14.4. HRMS (MH+) calc for C16H26N5OS: 336.1853. Found 336.1850.
    • Example 1.12
  • (3R,4S)-1-[(9-Deaza-adenin-9-yl)methyl]-3-hydroxy-4-(phenylthiomethyl)-pyrrolidine (16). The Mannich reaction general procedure (above) was followed to afford compound 16. 1H NMR (d4-MeOH) 8.22 (s, 1H), 7.74 (s, 1H), 7.33-7.15 (m, 2H), 4.43 (s, 2H), 4.26 (m, 1H), 3.62 (dd, J=11.7, 7.9 Hz, 2H), 3.48 (dd, J=12.0, 5.6 Hz, 1H), 3.25 (t, dd, J=12.0, 3.3 Hz, 1H), 3.15 (m, 2H), 2.85 (dd, J=13.5, 9.1 Hz, 1H), 2.43 (m, 1H). 13C NMR (d4-MeOH) 152.9, 152.1, 146.8, 136.8, 132.7, 131.4, 130.6, 128.1, 115.8, 106.3, 74.9, 60.6, 57.4, 49.7, 47.7, 36.3. HRMS (MH+) calc for C18H25N5OS: 356.1545. Found 356.1542.
    • Example 1.13
  • (3R,4S)-1-[(9-Deaza-adenin-9-yl)methyl]-4-(4-fluorophenylthiomethyl)-3-hydroxy-pyrrolidine (17). The Mannich reaction general procedure (above) was followed to afford compound 17. 1H NMR (d4-MeOH) 8.16 (s, 1H), 7.46 (s, 1H), 7.40-7.30 (m, 2H), 7.00-6.90 (m, 2H), 4.02-3.97 (m, 1H), 3.86-3.75 (m, 2H), 3.11 (dd, J=12.9, 5.9 Hz, 1H), 3.00 (t, J=8.7 Hz, 1H), 2.90-2.75 (m, 2H), 2.65-2.59 (m, 1H), 2.41-2.32 (m, 1H), 2.20-2.10 (m, 1H). 13C NMR (d4-MeOH) 165.5, 162.0, 152.5, 151.4, 147.4, 134.1, 134.0, 133.1, 130.4, 117.4, 117.1, 115.5, 112.9, 77.2, 62.7, 59.0, 49.3, 48.8, 39.1. HRMS (MH+) calc for C18H21N5OFS: 374.1445. Found 374.1438.
    • Example 1.14
  • (3R,4S)-4-(3-Chlorophenylthiomethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine (18). The Mannich reaction general procedure (above) was followed to afford compound 18. 1H NMR (d4-MeOH) 8.16 (s, 1H), 7.46 (s, 1H), 7.25-7.05 (m, 4H), 4.01-3.97 (m, 1H), 3.87-3.76 (m, 2H), 3.18 (dd, J=12.9, 5.9 Hz, 1H), 2.99 (dd, J=9.8, 7.9 Hz, 1H), 2.94-2.86 (m, 2H), 2.64 (dd, J=10.2, 4.3 1H), 2.41 (dd, J=9.9, 7.0 Hz, 1H), 2.26-2.15 (m, 1H). 13C NMR (d4-MeOH) 152.5, 151.4, 147.4, 140.7, 136.1, 131.6, 130.4, 129.8, 128.6, 127.4, 115.5, 112.8, 77.1, 62.6, 58.9, 49.3, 48.7, 37.4. HRMS (MH+) calc for C18H21N5OCIS: 390.1150. Found 390.1142.
    • Example 1.15
  • (3R,4S)-1-[(9-Deaza-adenin-9-yl)methyl]-3-hydroxy-4-(cyclohexylthiomethyl)pyrrolidine (19). A variation of the Mannich reaction general procedure (above) using 20% 1,4-dioxane in water as the solvent and 0.9 mol equiv. of 9-deazaadenine afforded the crude title compound 19 (333 mg, 79%) after column chromatography on silica eluting with CH2Cl2:MeOH:NH4OH (8:1.8:0.2 v/v/v). Residual impurities could be removed by column chromatography on silica eluting with CH2Cl2:NH3 (7N) in MeOH (9:1 v/v) to afford title compound 19 (144 mg, 34%). 1H NMR (MeOH-d4): 3 ppm: 8.15 (s, 1H), 7.50 (s, 1H), 3.97-3.92 (m, 1H), 3.82 (dd, J=19.1, 13.4 Hz, 2H), 3.06-3.00 (m, 1H), 2.84 (dd, J=10.3, 6.4 Hz, 1H), 2.75 (dd, J=12.5, 5.9 Hz, 1H), 2.67-2.58 (m, 2H), 2.48 (dd, J=12.5, 9.3 Hz, 1H), 2.37 (dd, J=9.8, 7.2 Hz, 1H), 2.20-2.08 (m, 1H), 1.94-1.92 (m, 2H), 1.74-1.72 (m, 2H), 1.60-1.58 (m, 1H), 1.36-1.19 (m, 5H). 13C NMR (MeOH-d4): δ ppm: 152.48, 151.35, 147.32, 130.50, 115.48, 112.74, 77.21, 62.62, 59.18, 49.38, 49.26, 45.10, 35.27, 35.20, 34.18, 27.48, 27.39.
    • Example 1.16
  • (3R,4S)-1-[(9-Deaza-adenin-9-yl)methyl]-3-hydroxy-4-(4-pyridylthiomethyl)-pyrrolidine (20). The Mannich reaction general procedure (above) was followed to afford compound 20. 1H NMR (D2O) 8.43 (d, J=7.2 Hz, 1H), 8.42 (s, 1H), 8.00 (s, 1H), 7.77 (d, J=7.2 Hz, 1H), 4.64 (s, 2H), 4.52-4.47 (m, 1H), 3.94 (dd, J=12.1, 8.0 Hz, 1H), 3.67 (dd, J=12.6, 5.7 Hz, 1H), 3.50-3.15 (m, 4H), 2.78-2.64 (m, 1H). 13C NMR (D2O) 163.9, 150.2, 144.6, 139.5, 135.4, 122.8, 113.2, 102.7, 73.0, 59.0, 55.9, 48.1, 44.4, 31.5. HRMS (MH+) calc for C17H21N6OS: 357.1492. Found 357.1509.
    • Example 1.17
  • (3R,4R)-1-[(9-Deaza-adenin-9-yl)methyl]-3-hydroxy-4-(methoxymethyl)-pyrrolidine (21). The Mannich reaction general procedure (above) was followed to afford compound 21. 1H NMR (d4-MeOH) 8.19 (s,. 1H), 7.63 (s, 1H), 4.18-4.05 (m, 3H), 3.40-2.28 (m, 3H), 3.30 (s, 3H), 3.10 (dd, J=11.0, 5.7 Hz, 1H), 2.95 (dd, J=11.0, 3.3 Hz, 1H), 2.77 (dd, J=10.8, 6.7 Hz, 1H), 2.41-2.29 (m, 1H). 13C NMR (d4-MeOH) 152.7, 151.8, 147.2, 131.6, 115.7, 109.5, 74.3, 74.1, 62.2, 59.6, 56.5, 49.4, 49.0. HRMS (MH+) calc for C13H20N5O2: 278.1612. Found 278.1626.
    • Example 1.18
  • (3R,4R)-4-(Benzyloxymethyl)-1-[(9-deaza-adenin-9-yl)methyl]-3-hydroxy-pyrrolidine (22). The Mannich reaction general procedure (above) was followed to afford compound 22. 1H NMR (d4-MeOH) 8.17 (s, 1H), 7.55 (s, 1H), 7.30-7.20 (m, 5H), 4.46 (bs, 2H), 4.10-4.00 (m, 3H), 3.55-3.38 (m, 2H), 3.23-3.18 (m, 1H), 2.98 (dd, J=10.7, 5.8 Hz, 1H), 2.85 (dd, J=10.7, 3.4 Hz, 1H), 2.68 (dd, J=10.4, 6.9 Hz, 1H), 2.38-2.30 (m, 1H). 13C NMR (d4-MeOH) 152.6, 151.7, 147.2, 139.9, 131.3, 129.8, 129.3, 129.1, 115.6, 110.4, 74.5, 74.3, 71.9, 62.3, 56.6, 49.4, 49.0.
    • Example 1.19
  • (3R,4R)-1-[(9-Deazaguanin-9-yl)methyl]-3-hydroxy-4-hydroxymethyl-pyrrolidine (23). (3R,4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidine hydrochloride (5) (154 mg, 1.0 mmol) and sodium acetate (82 mg, 1.0 mmol) were dissolved in water (2 mL) and to the solution were added aqueous formaldehyde (82 μL, 1.0 mmol) and 9-deazaguanine (Furneaux and Tyler, J. Org. Chem., 1999, 64, 8411-8412) (120 mg, 0.8 mmol). The reaction was stirred at 95° C. for 12 h. Silica gel (1.0 g) was added and the mixture was evaporated to dryness. Purification by chromatography on silica gel, using CH2Cl2:MeOH:NH4OH (5:4:1 v/v/v) as the eluent, afforded title compound 23 as the acetic acid salt. After conversion to the HCl salt and 1H and 13C NMR spectra analysis, the compound was found to be identical in all respects with that previously reported (Evans et al., J. Med. Chem. 2003, 46, 5271-5276).
    • Example 1.20
  • (3R,4S)-1-[(9-Deazahypoxanthin-9-yl]-3-hydroxy-4-(propylthomethyl)-pyrrolidine (24). The Mannich reaction general procedure (above) was followed to afford compound 24. 1H NMR (d4-MeOH/D2O) 7.99 (s, 1H), 7.53 (s, 1H), 4.06-3.98 (m, 1H), 3.92-3.80 (m, 2H), 3.06 (dd, J=9.8, 8.0 Hz, 1H), 2.90 (dd, J=10.5, 6.5 Hz, 1H), 2.79-2.65 (m, 2H), 2.52-2.38 (m, 4H), 2.22-2.15 (m, 1H), 1.57 (sextet, J=7.3 Hz, 2H), 0.95 (t, J=7.3 Hz, 3H). 13C NMR (d4-MeOH) 145.7, 143.7, 131.0, 113.6, 77.0, 62.1, 58.6, 48.9, 48.5, 35.9; 35.6, 24.2, 14.2.
    • Example 1.21
  • (3R,4S)-4-(Butylthiomethyl)-1-[(9-deazahypoxanth n-9-yl)methyl]-3-hydroxy-pyrrolidine (25). The Mannich reaction general procedure (above) was followed to afford compound 25. 1H NMR (d4-MeOH/CDCl3) 7.86 (s, 1H), 7.38 (s, 1H), 4.00-3.92 (m, 1H), 3.82-3.75 (m, 2H), 3.07 (dd, J=9.8, 8.0 Hz, 1H), 2.85-2.70 (m, 3H), 2.55-2.42 (m, 3H), 2.37-2.15 (m, 2H), 1.60-1.32 (m, 4H), 0.90 (t, J=7.3 Hz, 3H). 13C NMR (d4-MeOH/D2O) 156.6, 145.6, 142.9, 129.9, 119.6, 114.7, 77.4, 63.0, 59.6, 49.4, 49.1, 36.6, 33.6, 33.3, 23.5, 14.9. HRMS (MH+) calc for C16H25N4O2S: 337.1693. Found 337.1684.
    • Example 1.22
  • (3R,4S)-1-[(9-Deaza-6-chloro-purin-9-yl)methyl]-3-hydroxy-4-(2-phenylethyl)pyrrolidine (26). A variation of the Mannich reaction general procedure (above) using 0.9 mol equiv. of 6-chloro-9-deazapurine (K. Imai, Chem. Pharm. Bull., 1964, 12, 1030) afforded the title compound 26 (Scheme 2). In comparison to the standard procedure the reaction mixture did not form a solution but a brown slurry which was diluted with 1,4-dioxane before being preabsorbed onto silica gel. Column chromatography eluting with CH2Cl2: MeOH (4:1 v/v) followed by CH2Cl2:MeOH:NH4OH (5:4.5:0.5 v/v/v) gave 26 in 38% yield. 1H NMR (300 MHz, MeOH-d4): 5 ppm: 8.71 (s, 1H), 8.12 (s, 1H), 7.17 (s, 5H), 4.55 (s, 1H), 4.18 (m, 1H), 3.56 (m, 2H), 3.31 (m, 1H), 3.04 (dd, J=11.6, 7.7 Hz, 1H), 2.64 (m, 2H), 2.21 (m, 1H), 1.87 (m, 1H), 1.61 (m, 1H). 13C NMR (300 MHz, MeOH-d4): δ ppm: 151.62, 151.35, 145.02, 142.99, 138.11, 129.84, 129.82, 127.46, 126.81, 107.73, 75.68, 61.00, 58.48, 49.51, 47.56, 35.26, 34.88.
  • Figure US20100094003A1-20100415-C00007
    • Example 1.23
  • (3R,4S)-1-[(9-Deazaadenin-9-yl)methyl]-3-hydroxy-4-propyl-pyrrolidine (27). A variation of the Mannich reaction general procedure (above) using 0.9 mol equiv. of 9-deazaadenine afforded the crude title compound 27 (136 mg, 73%) after column chromatography on silica eluting with CH2Cl2:MeOH:NH4OH (8:1.8:0.2 v/v/v). Residual impurities could be removed by column chromatography on silica eluting with MeCN:NH4OH (4:1 v/v) to give 27 in 31% yield. NMR (300 MHz, MeOH-d4): δ ppm: 8.18 (s, 1H), 7.51 (s, 1H), 3.91-3.85 (m, 3H), 3.10 (dd, J=9.6, 8.0 Hz, 1H), 2.82-2.72 (m, 2H), 2.22 (dd, J=9.6, 8.0 Hz, 1H), 2.04-1.95 (m, 1H), 1.56-1.44 (m, 1H), 1.39-1.21 (m, 3H), 0.92-0.87 (m, 3H). 13C NMR (300 MHz, MeOH-d4): δ ppm: 152.52, 151.45, 147.37, 130.59, 115.55, 112.50, 77.94, 62.63, 59.94, 49.55, 48.59, 36.89, 22.67, 14.91.
    • Example 1.24
  • (3R,4S)-1-[(9-Deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-propyl-pyrrolidine (28). A variation of the Mannich reaction general procedure (above) using 0.9 mol equiv. of 9-deazahypoxanthine afforded the crude title compound 28 (90 mg, 61%) after column chromatography on silica eluting with CH2Cl2:MeOH:NH4OH (5:4.5:0.5 v/v/v). Residual impurities (9-deazahypoxanthine) could be removed by column chromatography on silica eluting with CH2Cl2:MeOH:NH4OH (8:1.8:0.2 v/v/v) to give 28 in 36% yield. NMR (300 MHz, MeOH-d4, ˜30% CDCl3): δ ppm: 7.86 (s,1H), 7.39 (s, 1H), 3.89-3.76 (m, 3H), 3.09 (dd, J=9.5, 7.9 Hz, 1H), 2.79-2.69 (m, 2H), 2.18-2.12 (m, 1H), 2.05-1.96 (m, 1H), 1.55-1.46 (m, 1H), 1.41-1.23 (m, 3H), 0.94-0.89 (m, 3H). 13C NMR (300 MHz, MeOH-d4, ˜30% CDCl3): δ ppm: 145.59, 142.99, 129.93, 114.50, 78.14, 62.95, 60.24, 49.78, 48.94, 37.07, 22.80, 15.29.
    • Preparative Example 1 Procedures for the synthesis of (3R,4S)-3-hydroxy-4-(alkyl-, aralkyl-, and aryl-thiomethyl)pyrrolidines
  • General Preparative method. 4-Substituted-4-thiopyrrolidines were prepared essentially following the method detailed in Preparative Example 1.01 for compound 32, but with the modifications noted for each Preparative Example and using the appropriate sodium thiolate. In cases when the sodium thiolate was not directly available it was pre-formed by treating a stirred mixture of NaH (2.85 mmol) in DMF (5 mL) at 0° C. with the appropriate thiol (2.85 mmol). After stirring the mixture for 10 min, a solution of the mesylate (450 mg, 1.53 mmol) was added as a solution in DMF (5 mL) and the mixture was stirred at RT until the complete consumption of the mesylate was observed (0.5-4 h) by TLC.
    • Preparative Example 1.01
  • (3R,4S)-3-Hydroxy-4-(methylthiomethyl)-pyrrolidine (32), Scheme 3. Methanesulfonyl chloride (0.950 mL, 12.3 mmol) was added to a solution of (3R,4R)-N-tert-butoxycarbonyl-3-hydroxy-4-hydroxymethyl-pyrrolidine (29) (Evans et al., J. Med. Chem., 2003, 46, 5271-5276) (2.16 g, 9.94 mmol) and diisopropylethyl amine (2.65 mL, 15.0 mmol) in DCM (40 mL) cooled to −78° C. over 5 min. After stirring at −78° C. for 40 min, aqueous 2M HCl was added, the organic phase was separated. The aqueous phase was extracted with DCM (×2). The combined organic extract was washed with sat. aqueous NaHCO3 then brine and dried (MgSO4). Normal processing and chromatography gave (1.99 g, 6.74 mmol, 68%) of mesylate 30 as a colourless glass. HRMS (MH+) calc for C11H21NO6SNa: 318.0982. Found 318.0979. A solution of mesylate 30 (450 mg, 1.53 mmol) in DMF (5 mL) was added to a stirred solution of sodium thiomethoxide (200 mg, 2.85 mmol) in DMF (3 mL) and the mixture was stirred for 1 h. Toluene (50 mL) and H2O (50 mL) were added and shaken, the phases separated, the organic layer dried (MgSO4) and the solvent removed at reduced pressure. The crude product that was purified by chromatography on silica, eluting with 10-50% EtOAc/petroleum ether to afford intermediate 31 (210 mg, 0.849 mmol, 55%). A solution of this material in methanol (3 mL) was treated with cHCl (1 mL). After 1 h, the solution was concentrated to dryness to give title compound 32 as a solid residue (0.830 mmol, 98%). The solid residue was dissolved in H2O (10 mL) or D2O (for NMR samples) and the solvent removed (×3). 1H NMR (D2O) 4.40 (q, J=3.1 Hz, 1H), 3.67 (dd, J=12.0, 6.6 Hz, 1H), 3.50 (dd, J=12.8, 5.1 Hz, 1H), 3.28 (dd, J=12.8, 3.0 Hz, 1H), 3.22 (dd, J=8.7, 3.4 Hz, 1H), 2.73-2.66 (m, 1H), 2.58-2.50 (m, 2H), 2.40-2.30 (m, 2H) 2.13 (s, 3H). 13C NMR (D2O) 73.5, 51.5, 48.6, 45.2, 34.3, 14.9.
  • Figure US20100094003A1-20100415-C00008
    • Preparative Example 1.02
  • (3R,4S)-4-(Ethylthiomethyl)-3-hydroxy-pyrrolidine (33). Following the general procedure outlined above, mesylate 30 (260 mg, 0.880 mmol) was processed to afford title compound 33 (100 mg, 0.506 mmol, 58%). 1H NMR (D2O) 4.30-4.24 (m, 1H), 3.53 (dd, J=12.3, 7.2 Hz, 1H), 3.37 (dd, J=12.8, 5.2 Hz, 1H), 3.14 (dd, J=12.8, 3.1 Hz, 1H), 3.07 (dd, J=12.2, 5.7 Hz, 1H), 2.65-2.55 (m, 1H), 2.46 (q, J=7.4 Hz, 2H), 2.40-2.30 (m, 2H) 1.09 (t, J=7.4 Hz, 3H). 13C NMR (D2O) 73.6, 51.5, 48.6, 45.6, 31.7, 26.0, 14.4. HRMS (MH+) calc for C7H16NOS: 162.0947. Found 162.0952.
    • Preparative Example 1.03
  • (3R,4S)-3-Hydroxy-4-(propylthiomethyl)-pyrrolidine (34). Following the general procedure outlined above, mesylate 30 (264 mg, 0.894 mmol) was processed to afford 34 (139 mg, 0.656 mmol, 73%). 1H NMR (D2O) 4.41-4.37 (m, 1H), 3.67 (dd, J=12.3, 7.2 Hz, 1H), 3.50 (dd, J=12.8, 5.2 Hz, 1H), 3.27 (dd, J=12.8, 3.1 Hz, 1H), 3.21 (dd, J=12.2, 5.6 Hz, 1H), 2.76-2.71 (m, 1H), 2.61-2.50 (m, 4H), 1.59 (sextet, J=7.3 Hz), 0.95 (t, J=7.3 Hz, 3H). 13C NMR (D2O) 73.6, 51.5, 48.6, 45.7, 34.1, 32.1, 22.7, 13.1. HRMS (MH+) calc for C8H18NOS: 176.1104. Found 176.1106.
    • Preparative Example 1.04
  • (3R,4S)-3-Hydroxy-4-(isopropylthiomethyl)-pyrrolidine hydrochloride (35). To a solution of 2-propanethiol (0.36 mL, 3.9 mmol) in DMF (10 mL) at 0° C. was added 60% NaH (145 mg, 3.6 mmol). After 10 min. of stirring a solution of the mesylate 30 (565 mg, 1.91 mmol) in DMF (10 mL) was added. Stirring was continued while the reaction was allowed to attain r.t. After completion, the reaction was quenched with aq. NaHCO3, toluene was added and the reaction was processed normally to give the crude intermediate which was subjected to column chromatography on silica eluting with petroleum ether. EtOAc (4:1→1:1 v/v) to give the clean intermediate (3R,4S)-N-tert-butoxycarbonyl-3-hydroxy-4-(isopropylthiomethyl)-pyrrolidine as a colourless syrup (490 mg, 97%). NMR (300 MHz, CDCl3): δ ppm: 4.18-4.11 (m, 1H), 3.72-3.60 (m, 2H), 3.28-3.18 (m, 1H), 3.13 (dd, J=11.1, 6.7 Hz, 1H), 2.95 (sept., J=6.7 Hz, 1H), 2.69-2.50 (m, 2H), 2.33-2.22 (m, 1H), 1.46 (s, 9H), 1.29, 1.27 (s, 3H each). 13C NMR (300 MHz, CDCl3): δ ppm: (note that some peaks are doubled due to slow conversion of rotamers) 154.93, 79.97, (75.48, 74.64), (52.81, 52.55), (49.69, 49.42), (46.13, 45.35), 35.71, 32.32, 28.87, 23.73, 23.69. A solution of this material in MeOH (10 mL) was treated with 12 N (conc.) HCl (4 mL) at 40° C. for 30 min. to give the crude title compound 35 which was used directly in a Mannich-type reaction.
    • Preparative Example 1.05
  • (3R,4S)-4-(Butylthiomethyl)-3-hydroxy-pyrrolidine (36). Following the general procedure outlined above, mesylate 30 (438 mg, 1.48 mmol) was processed to afford 36 (284 mg, 1.25 mmol, 84%). 1H NMR (D2O) 4.40-4.36 (m, 1H), 3.66 (dd, J=12.3, 7.2 Hz, 1H), 3.48 (dd, J=12.8, 5.2 Hz, 1H), 3.26 (dd, J=12.8, 3.1 Hz, 1H), 3.21 (dd, J=12.2, 5.6 Hz, 1H), 2.76-2.70 (m, 1H), 2.62-2.50 (m, 4H), 1.61-1.51 (m, 2H), 1.40-1.33 (m, 2H), 0.86 (t, J=7.3 Hz, 3H). 13C NMR (D2O) 73.5, 51.5, 48.6, 45.7, 32.2, 31.7, 31.3, 21.7, 13.3. HRMS (MH+) calc for C9H20NOS: 190.1260. Found 190.1257.
    • Preparative Example 1.06
  • (3R,4S)-3-Hydroxy-4-(phenylthiomethyl)-pyrrolidine (37). Following the general procedure outlined above, mesylate 30 (300 mg, 1.00 mmol) was processed to afford 37 (692 mg, 0.69 mmol). 1H NMR (D2O) 7.51-7.24 (m, 5H), 4.38-4.34 (m, 1H), 3.56 (dd, J=12.2, 7.7 Hz, 1H), 3.45 (dd, J=12.6, 5.2 Hz, 1H), 3.26-3.00 (m, 3H), 2.88 (dd, J=13.7, 8.3 Hz, 1H), 2.48-2.37 (m, 1H). 13C NMR (D2O) 134.5, 130.5, 129.9, 127.6, 73.4, 51.5, 48.4, 45.5, 34.3.
    • Preparative Example 1.07
  • (3R,4S)-(4-Fluorophenyllthiomethyl)-3-hydroxy-4-pyrrolidine (38). Following the general procedure outlined above, mesylate 30 (281 mg, 0.951 mmol) was processed to afford 38 (160 mg, 0.607 mmol, 64%). 1H NMR (D2O) 7.49-7.42 (m, 2H), 7.19-7.06 (m, 2H), 4.41-4.36 (m, 1H), 3.60 (dd, J=12.3, 7.7 Hz, 1H), 3.48 (dd, J=12.8, 5.2 Hz, 1H), 3.27-3.16 (m, 2H), 3.07 (dd, J=13.8, 6.9 Hz, 1H), 2.88 (dd, J=13.8, 8.3 Hz, 1H), 2.45-2.38 (m, 1H). 13C NMR (D2O) 164.2, 160.9, 133.7, 133.6, 129.4, 116.9, 116.6, 73.3, 51.5, 48.4, 45.5, 35.5. HRMS (MH+) calc for C11H15NOSF: 228.0853. Found 228.0856.
    • Preparative Example 1.08
  • (3R,4S)-(4-Chlorophenylthiomethyl)-3-hydroxy-4-pyrrolidine (39). Following the general procedure outlined above, mesylate 30 (245 mg, 0.83 mmol) was processed to afford 39 (212 mg, 0.76 mmol, 91%). 1H NMR (d4-MeOH) 7.51-7.39 (m, 2H), 7.35-7.31 (m, 2H), 4.38-4.33 (m, 1H), 3.59 (dd, J=12.0, 7.6 Hz, 1H), 3.47 (dd, J=12.4, 4.9 Hz, 1H), 3.28-3.18 (m, 3H), 2.93 (dd, J=13.6, 9.0 Hz, 1H), 2.49-2.38 (m, 1H). 13C NMR (D2O) 135.7, 134.1, 132.9, 130.8, 74.8, 52.9, 49.6, 47.5, 35.8.
    • Preparative Example 1.09
  • (3R,4S)-4-(3-Chlorophenylthiomethyl)-3-hydroxy-pyrrolidine (40). Following the general procedure outlined above, mesylate 30 (300 mg, 1.02 mmol) was processed to afford 40 (192 mg, 0.685 mmol, 67%). 1H NMR (D2O) 7.33-7.15 (m, 4H), 4.39-4.35 (m, 1H), 3.59 (dd, J=12.2, 7.7 Hz, 1H), 3.47 (dd, J=12.7, 5.1 Hz, 1H), 3.28-3.04 (m, 3H), 2.89 (dd, J=13.7, 8.3 Hz, 1H), 2.49-2.41 (m, 1H). 13C NMR (D2O) 136.9, 134.7, 131.0, 129.3, 128.1, 127.2, 73.4, 51.5, 48.4, 45.3, 34.0. HRMS (MH+) calc for C11H15NOSCl: 244.0557(4). Found 244.0556(8).
    • Preparative Example 1.10
  • (3R,4S)-4-(Benzylthiomethyl)-3-hydroxy-pyrrolidine (41). Following the general procedure outlined above, mesylate 30 (1.10 g, 3.7 mmol) was processed to afford 41 (730 mg, 2.81 mmol, 76%). 1H NMR (D2O) 7.40-7.27 (m, 5H), 4.26-4.22 (m, 1H), 3.74 (s, 2H), 3.56 (dd, J=12.4, 7.2 Hz, 1H), 3.37 (dd, J=12.8, 5.2 Hz, 1H), 3.21 (dd, J=12.8, 3.0 Hz, 3H), 2.07 (dd, J=12.4, 5.5 Hz, 1H), 2.61-2.52 (m, 1H), 2.47-2.34 (m, 2H). 13C NMR (D2O) 138.7, 129.5, 129.3, 127.9, 73.5, 51.5, 48.5, 45.4, 35.9, 31.8. HRMS (MH+) calc for C12H18NOS: 224.1109. Found 224.1102.
    • Preparative Example 1.11
  • (3R,4R)-3-Hydroxy-4-(methoxymethyl)-pyrrolidine (42), Scheme 4. The diol 29 was manipulated according to Scheme 4 to afford 42. 1H NMR (D2O) 4.30-4.26 (m, 1H), 3.52-3.28 (m, 4H), 3.22 (s, 3H), 3.15-3.00 (m, 2H), 2.48-2.37 (m, 1H). 13C NMR (D2O) 72.1, 71.6, 58.8, 52.0, 46.7, 45.7. HRMS (MH+) calc for C8H14NO2: 132.1019. Found 132.1012.
  • Figure US20100094003A1-20100415-C00009
    • Preparative Example 1.12
  • (3R,4R)-4-(Benzyloxymethyl)-3-hydroxy-pyrrolidine (43), Scheme 4. The diol 29 was manipulated according to Scheme 4 to afford 43. 1H NMR (D2O, free base) 7.32-7.15 (m, 5H), 4.36 (s, 2H), 3.92-3.85 (m, 1H), 3.35 (dd, J=9.8, 7.0 Hz, 1H), 3.24 (dd, J=9.8, 7.8 Hz, 1H), 2.97 (dd, J=11.8, 7.9 Hz, 1H), 2.75 (dd, J=12.4, 5.5 Hz, 1H), 2.57 (dd, J=12.4, 3.4 Hz, 1H), 2.36 (dd, J=11.8, 5.7 Hz, 1H), 2.15-2.05 (m, 1H). 13C NMR (D2O) 137.6, 129.0, 128.8, 128.6, 74.7, 73.1, 71.0, 53.2, 48.0, 47.6. HRMS (MH+) calc for C12H18NO2: 208.1332. Found 208.1329.
    • Preparative Example 1.13
  • (3R,4S)-4-(Cyclohexylthiomethyl)-3-hydroxy-pyrrolidine hydrochloride (44) To a solution of cyclohexylmercaptan (0.47 mL, 3.84 mmol) in DMF (10 mL) at 0° C. was added 60% NaH (145 Mg, 3.6 mmol). After 10 min. of stirring, a solution of the mesylate 30 (565 mg, 1.91 mmol) in DMF (10 mL) was added. Stirring was continued while the reaction was allowed to attain r.t. After completion, the reaction was quenched with aq. NaHCO3, toluene was added and the reaction was processed normally to give the crude intermediate which was subjected to column chromatography on silica eluting with petroleum ether: EtOAc (1:1 v/v) to give the clean intermediate (3R,4S)-N-tert-butoxycarbonyl-3-hydroxy-4-(cyclohexylthiomethyl)-pyrrolidine as a colourless syrup (428 mg, 71%). NMR (300 MHz, CDCl3): δ ppm: 4.17-4.09 (m, 1H), 3.72-3.60 (m, 2H), 3.28-3.18 (m, 1H), 3.15-3.09 (m, 1H), 2.74-2.64 (m, 2H), 2.60-2.53 (m, 1H), 2.32-2.23 (m, 1H), 1.96 (m, 2H), 1.81-1.77 (m, 2H), 1.66-1.61 (m, 1H), 1.45 (s, 9H), 1.35-1.24 (m, 5H). 13C NMR (300 MHz, CDCl3): δ ppm: (note that some peaks are doubled due to slow conversion of rotamers) 154.91, 79.94, (75.57, 74.72), (52.80, 52.55), (49.70, 49.43), (46.24, 45.41), 44.26, 33.99, 33.93, 31.90, 28.87, 26.43, 26.12. A solution of this material in MeOH (10 mL) was treated with 12 N (conc.) HCl (4 mL) at 40° C. for 30 min. to give the crude title compound 44 which was used directly in a Mannich-type reaction.
    • Preparative Example 1.14
  • (3R,4S)-3-Hydroxy-4-(4-pyridylthiomethyl)-pyrrolidine (45). Following the general procedure outlined above, mesylate 30 (348 mg, 1.18 mmol) was processed to afford 45 (105 mg, 0.426 mmol, 36%). 1H NMR (D2O) 8.42 (d, J=7.2 Hz, 2H), 7.82 (d, J=7.2 Hz, 2H), 4.51-4.46 (m, 1H), 3.74 (dd, J=12.4, 7.8 Hz, 1H), 3.57 (dd; J=12.8, 5.5 Hz, 1H), 3.44 (dd, J=13.6, 7.3 Hz, 1H) 3.34-3.22 (m, 3H), 2.78-2.60 (m, 1H). 13C NMR (D2O) 164.1, 139.4, 122.9, 73.4, 51.4, 48.4, 44.3, 31.3. HRMS (MH+) calc for C10H15N2OS: 211.0900. Found 211.0908.
    • Preparative Example 2.01
  • (3R,4S)-3-Hydroxy-4-(2-phenylethyl)-pyrrolidine hydrochloride (49), Scheme 5. To a suspension of benzyltriphenylphosphonium bromide (1.75 g, 4.97 mmol) in dry THF (10 mL) under argon at 0° C. was added 1.6 M BuLi in THF (2.33 mL, 3.73 mmol) and the deep red solution left stirring without cooling for 10 min. After re-cooling to 0° C., the aldehyde 46 (335 mg, 1.56 mmol) [G. B. Evans, R. H. Fumeaux, A. Lewandowicz, V. L. Schramm, and P. C. Tyler, Second-Generation Transition State Analogues of Human Purine Nucleoside Phosphorylase, J. Med. Chem., 46 (2003) 5271-5276] in THF (5 mL) was added and the mixture stirred at r.t. for 12 h. The reaction was then quenched with water (1 mL) and extracted with dichloromethane (100 mL). The organic phase was washed with sat. aq. NaHCO3 (15 mL) then water (15 mL), dried (MgSO4) and concentrated in vacuo. The residue was subjected to chromatography to afford a ca. 1:3 cis/trans mixture of (3R,4S)-N-tert-butoxycarbonyl-3-hydroxy-4-(2-phenylethenyl)-pyrrolidine (47) as a syrup (290 mg, 64%). 1H NMR (300 MHz, CDCl3): δ ppm: trans: 7.28 (m, 5H), 6.49 (d, J=15.9 Hz, 1H), 6.03 (dd, J=15.9, 8.1 Hz, 1H), 4.11 (m, 1H), 3.67 (m, 2H), 3.32 (m, 2H), 2.83 (m, 1H), 1.46 (s, 9H); cis: 7.27 (m, 5H), 6.58 (d, J=11.6 Hz, 1H), 5.43 (dd, J=11.6 Hz, 10.0 Hz, 1H), 4.11 (m, 1H), 3.65 (m, 2H), 3.21 (m, 2H), 2.88 (m, 1H), 1.44 (s, 9H). To a solution of intermediate 47 (290 mg, 1.00 mmol) in ethanol (20 mL) was added 10% Pd/C (250 mg) and the suspension was stirred under an atmosphere of hydrogen for 12 h. After filtration, the solvent was removed in vacuo to give (3R,4S)-N-tert-butoxycarbonyl-3-hydroxy-4-(2-phenylethyl)pyrrolidine (48) as a syrup, 254 mg (87%). 1H NMR (300 MHz, CDCl3): δ ppm: 7.10 (m, 5H), 4.00 (m, 1H), 3.47 (m, 2H), 3.07 (m, 2H), 2.67 (m, 2H), 2.04 (m, 1H), 1.83 (m, 1H), 1.54 (m, 1H), 1.45 (s, 9H). 13C NMR (300 MHz, CDCl3): δ ppm (note that some peaks are doubled due to slow conversion of rotamers): 155.17, 142.03, 128.83, 128.71, 126.37, 79.88, (74.94, 71.26), (53.17, 52.90), (49.90, 49.34), (46.11, 45.52), 34.41, 33.69, 28.91. To a solution of intermediate 48 (254 mg, 0.87 mmol) in methanol (10 mL) was added 12N (conc.) HCl (4 mL) and the solution stirred at 40° C. for 30 min. After removal of the solvent in vacuo and azeotroping with toluene, the crude title compound (3R,4S)-3-Hydroxy-4-(2-phenylethyl)pyrrolidine hydrochloride 49 was obtained as a solid (202 mg, 0.89 mmol, 102%). 1H NMR (300 MHz, MeOH-d4): δ ppm: 7.14 (m, 5H), 4.22 (m, 1H), 3.52 (dd, J=11.8, 7.4 Hz, 1H), 3.39 (dd, J=12.3, 4.9 Hz, 1H), 3.14 (dd, J=12.3, 2.8 Hz, 1H), 3.02 (dd, J=11.8 Hz, 1H), 2.71 (m, 2H), 2.20 (m, 1H), 1.84 (m, 1H), 1.62 (m, 1H). 13C NMR (300 MHz, MeOH-d4): δ ppm: 142.94, 129.93, 129.89, 127.56, 75.56, 52.90, 48.55, 47.28, 35.18, 34.44.
  • Figure US20100094003A1-20100415-C00010
    • Preparative Example 2.02 (3R,4S)-3-Hydroxy-4-propyl-pyrrolidine hydrochloride (52)
  • The synthesis of this compound follows the same general route outlined in scheme 5 [see Preparative Example 2.01]. To a suspension of ethyltriphenylphosphonium bromide (2.9 g, 6.93 mmol) in dry THF (15 mL) under argon at 0° C. was added 1.6 M BuLi in THF (4 mL, 6.40 mmol) and the deep red solution left stirring without cooling for 10 min. After re-cooling to 0° C., the aldehyde 46 (580 mg, 2.69 mmol) in THF (10 mL) was added and the mixture stirred at r.t. for 12 h. The reaction was then quenched with water (1 mL) and extracted with dichloromethane (100 mL). The organic phase was washed with sat. aq. NaHCO3 (15 mL) then water (15 mL), dried over MgSO4) and concentrated in vacuo. The residue was subjected to chromatography to afforded (3R,4S)-N-tent-butoxycarbonyl-3-hydroxy-4-propenyl-pyrrolidine (50) as a light yellow syrup (165 mg, 27%). To a solution of intermediate 50 (165 mg, 0.73 mmol) in ethanol (10 mL) was added 10% Pd/C (60 mg) and the suspension was stirred under an atmosphere of hydrogen for 3 h. After filtration, the solvent was removed in vacuo to give (3R,4S)-N-tert-butoxycarbonyl-3-hydroxy-4-propyl-pyrrolidine (51) as a syrup (172 mg, 102%). 1H NMR (300 MHz, CDCl3): δ ppm: 3.98-3.96 (m, 1H), 3.61-3.57 (m, 3H), 3.22-3.18 (m, 1H), 3.10-3.01 (m, 1H), 2.03 (m, 1H), 1.45 (s, 9H), 1.41-1.31 (m, 2H), 1.24-1.12 (m, 1H), 0.94-0.89 (m, 3H). 13C NMR (300 MHz, CDCl3): δ ppm (note that some peaks are doubled due to slow conversion of rotamers): 155.20, 79.69, (75.53, 74.76), (53.10, 52.80), (49.94, 49.38), (46.19, 45.67), 34.04, 28.83, 21.27, 14.47. To a solution of intermediate 51 (172 mg, 0.75 mmol) in methanol (10 mL) was added 12N (conc.) HCl (4 mL) and the solution stirred at 40° C. for 30 min. After removal of the solvent in vacuo and azeotroping with toluene, the crude title compound (3R,4S)-3-hydroxy-4-propyl-pyrrolidine hydrochloride (52) was obtained as a syrup (138 mg, 0.83 mmol, 111%). 1H NMR (300 MHz, MeOH-d4): δ ppm: 4.20-4.16 (m, 1H), 3.59-3.52 (m, 1H), 3.44-3.39 (m, 1H), 3.19-3.14 (m, 1H), 3.05-2.99 (m, 1H), 2.23-2.17 (m, 1H), 1.55-1.28 (m, 4H), 0.98-0.94 (m, 3H). 13C NMR (300 MHz, MeOH-d4): δ ppm: 75.65, 52.82, 50.30, 47.45, 34.69, 22.30, 14.78.
    • Preparative Example 3.01
  • 9-Deaza-adenine. 6-Chloro-9-deazapurine (3 g, 19.5 mmol) was added to a saturated solution of ammonia in ethanol (30 mL). The resulting suspension was heated at 130° C. for 16 h in a sealed tube. The homogeneous solution was cooled, flash silica gel was added, and the suspension concentrated in vacuo. The resultant solid was loaded onto the top of a column of silica gel and eluted with methanol/CH2Cl2 (4:1 v/v) to afford 9-deaza-adenine as a pale yellow solid (2.16 g, 80%). 13C NMR (d4-MeOH) 5 ppm: 153.1, 149.9, 145.2, 131.3, 113.8, 101.6.
    • Preparative Example 4.01
  • (3R,4R)-3-Hydroxy-4-methanesulfonyloxy-pyrrolidine (53). A solution of HCl in 1,4-dioxane (4M, 2 mL) was added to a stirred solution of the mesylate 30 (169 mg, 0.572 mmol) in methanol (3 mL). After stirring at RT for 12 h, the solvents were removed in vacuo to give a residue to which methanol (×2) and then D2O was added and evaporated to give title compound 53 (120 mg, 0.518 mmol, 91%). 1H NMR (D2O) 4.55-4.35 (m, 3H), 3.74 (dd, J=12.5, 8.4 Hz, 1H), 3.50 (dd, J=12.7, 5.3 Hz, 1H), 3.35-3.20 (m, 2H), 3.25 (s, 3H), 2.82-2.67 (m, 1H). 13C NMR (D2O) 71.3, 69.2, 52.0, 46.0, 45.3, 36.9. HRMS (MH+) calc for C6H14NO4S: 196.0638. Found 196.0648.
  • Although the invention has been described by way of example, it should be appreciated that variations or modifications may be made without departing from the scope of the invention. Furthermore, when known equivalents exist to specific features, such equivalents are incorporated as if specifically referred to in the specification.
    • INDUSTRIAL APPLICABILITY
  • The present invention provides a useful synthetic route to compounds that are inhibitors of PNP, PPRT, MTAN, MTAP and/or NH. The compounds may be useful in the treatment of diseases in which the inhibition of PNP, PPRT, MTAN, MTAP and/or NH is desirable. Such diseases include cancer, bacterial infection, protozoal infection or T-cell mediated diseases.

Claims (17)

1. A process for preparing a compound of the formula (I)
Figure US20100094003A1-20100415-C00011
wherein:
V is selected from CH2 and NH, and W is NR1; or
V is NR1, and W is selected from CH2 and NH;
X is selected from CH2 and CHOH in the R or S-configuration, except where W is selected from NH and NR1, then X is CH2;
Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH and NR1, then Y is hydrogen;
Z is selected from hydrogen, halogen, hydroxy, a sulfonate leaving group, SQ, OQ and Q, where Q is an optionally substituted alkyl, aralkyl or aryl group; and
R1 is a radical of the formula (II)
Figure US20100094003A1-20100415-C00012
wherein:
A is selected from N, CH and CR2, where R2 is selected from halogen, optionally substituted alkyl, aralkyl or aryl, OH, NH2, NHR3, NR3R4 and SR5, where R3, R4 and R5 are each optionally substituted alkyl, aralkyl or aryl groups;
B is selected from OH, NH2, NHR6, SH, hydrogen and halogen, where R6 is an optionally substituted alkyl, aralkyl or aryl group;
D is selected from OH, NH2, NHR7, hydrogen, halogen and SCH3, where R7 is an optionally substituted alkyl, aralkyl or aryl group; and
E is selected from N and CH;
including reacting a compound of the formula (III)
Figure US20100094003A1-20100415-C00013
wherein:
V is selected from CH2 and NH, and W is NH; or
V is NH, and W is selected from CH2 and NH;
X is selected from CH2 and CHOH in the R or S-configuration, except where W is NH, then X is CH2;
Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH, then Y is hydrogen; and
Z is selected from hydrogen, halogen, hydroxy, a sulfonate leaving group, SQ, OQ and Q, where Q is an optionally substituted alkyl, aralkyl or aryl group;
with a compound of the formula (IV)
Figure US20100094003A1-20100415-C00014
wherein A, B, D, and E are as defined above;
and with formaldehyde or a formaldehyde equivalent.
2. The process of claim 1, wherein Z is hydrogen, halogen, hydroxy, SQ or OQ, where Q is an optionally substituted alkyl, aralkyl or aryl group.
3. The process of claim 1, wherein A is CH.
4. The process of claim 1, wherein Y is H.
5. The process of claim 1, wherein W is NR1, V is CH2 and X is CH2.
6. The process of claim 5, wherein R1 is a radical of formula (II), where A is CH and E is N.
7. The process of claim 1, wherein D is H or NH2.
8. The process of claim 1, wherein B is NH2, OH or Cl.
9. The process of claim 1, wherein Z is methanesulfonate, p-toluenesulfonate or trifluoromethanesulfonate.
10. The process of claim 9, wherein Z is methanesulfonate.
11. The process of claim 1, wherein the compounds of formula (III) and (IV) are reacted with formaldehyde.
12. The process of claim 1, wherein the compounds of formula (III) and (IV) are reacted with a formaldehyde equivalent which is paraformaldehyde.
13. (canceled)
14. A compound of formula (I) prepared by the a process according to claim 1.
15. A process for preparing a compound of formula (I) as defined in claim 1 comprising:
(i) reacting a compound of formula (III) as defined in claim 1 with a compound of formula (IV) as defined in claim 1 and with formaldehyde or a formaldehyde equivalent, where any one or more of V, W, X, Y and Z of the compound of formula (III) is protected with a suitable protecting group; and
(ii) removing the one or more protecting groups to give the compound of formula (I).
16. A process for preparing a compound of formula (I) as defined in claim 1 comprising:
(i) reacting a compound of formula (III) as defined in claim 1 with a compound of formula (IV) as defined in claim 1 and with formaldehyde or a formaldehyde equivalent, where any one or more of A, B, D and E of the compound of formula (IV) is protected with a suitable protecting group; and
(ii) removing the one or more protecting groups to give the compound of formula (I).
17. A process of preparing a compound of formula (1) as defined in claim 1 comprising:
(i) reacting a compound of formula (III) as defined in claim 1 with a compound of formula (IV) as defined in claim 1 and with formaldehyde or a formaldehyde equivalent, where any one or more of V, W, X, Y and Z of the compound of formula (III) is protected with a suitable protecting group and where any one or more of A, B, D and E of the compound of formula (IV) is protected with a suitable protecting group; and
(ii) removing the one or more protecting groups to give the compound of formula (I).
US12/653,319 2003-02-04 2009-12-11 Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases Abandoned US20100094003A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/653,319 US20100094003A1 (en) 2003-02-04 2009-12-11 Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NZ523970A NZ523970A (en) 2003-02-04 2003-02-04 Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
NZ523970 2003-02-04
US10/543,380 US7655795B2 (en) 2003-02-04 2004-01-30 Process for preparing pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
PCT/NZ2004/000017 WO2004069856A1 (en) 2003-02-04 2004-01-30 Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases
US12/653,319 US20100094003A1 (en) 2003-02-04 2009-12-11 Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/NZ2004/000017 Division WO2004069856A1 (en) 2003-02-04 2004-01-30 Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases
US11/543,380 Division US20080085033A1 (en) 2006-10-04 2006-10-04 Determining orientation through the use of retroreflective substrates

Publications (1)

Publication Number Publication Date
US20100094003A1 true US20100094003A1 (en) 2010-04-15

Family

ID=32844996

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/543,380 Expired - Fee Related US7655795B2 (en) 2003-02-04 2004-01-30 Process for preparing pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US12/653,319 Abandoned US20100094003A1 (en) 2003-02-04 2009-12-11 Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/543,380 Expired - Fee Related US7655795B2 (en) 2003-02-04 2004-01-30 Process for preparing pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases

Country Status (16)

Country Link
US (2) US7655795B2 (en)
EP (1) EP1590360B1 (en)
JP (1) JP4806746B2 (en)
KR (1) KR101185120B1 (en)
CN (1) CN100357308C (en)
BR (1) BRPI0407210A (en)
CA (1) CA2514992C (en)
CY (1) CY1113297T1 (en)
DK (1) DK1590360T3 (en)
ES (1) ES2391043T3 (en)
HK (1) HK1089448A1 (en)
NZ (1) NZ523970A (en)
PT (1) PT1590360E (en)
RU (1) RU2334757C2 (en)
SI (1) SI1590360T1 (en)
WO (1) WO2004069856A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280334A1 (en) * 2004-06-04 2008-11-13 Dirk Henning Lenz Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds
US20090227532A1 (en) * 2006-02-22 2009-09-10 Richard Hubert Furneaux Analogues of Coformycin and Their Use for Treating Protozoan Parasite Infections
US20090233948A1 (en) * 2005-05-20 2009-09-17 Gary Brian Evans Inhibitors of nucleoside phosphorylases and nucleosidases
US20090239885A1 (en) * 2002-08-21 2009-09-24 Gary Brian Evans Inhibitors of nucleoside phoshorylases and nucleosidases
US20090325986A1 (en) * 2005-12-15 2009-12-31 Richard Hubert Furneaux Deazapurine Analogs of 1'-Aza-L-Nucleosides
US20100168141A1 (en) * 2006-12-22 2010-07-01 Gary Brian Evans Azetidine analogues nucleosidase and phosphorylase inhibitors
US20110046167A1 (en) * 2006-09-07 2011-02-24 Keith Clinch Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase
US20110092521A1 (en) * 2006-02-24 2011-04-21 Richard Hubert Furneaux Methods of Treating Diseases Using Inhibitors of Nucleoside Phosphorylases and Nucleosidases
US20110190265A1 (en) * 2008-09-22 2011-08-04 Schramm Vern L Methods and compositions for treating bacterial infections by inhibiting quorum sensing
US8853224B2 (en) 2006-09-07 2014-10-07 Industrial Research Limited Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
US8916571B2 (en) 2006-02-24 2014-12-23 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating cancer using inhibitors of 5′-methylthioadenosine phosphorylase
US9493465B2 (en) 2009-07-17 2016-11-15 Victoria Link Limited 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
ATE425165T1 (en) * 1999-04-08 2009-03-15 Ind Res Ltd METHOD FOR PREPARING NUCLEOSIDE METABOLISM INHIBITORS
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
CA2615549A1 (en) * 2005-07-27 2007-02-08 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
CN101094080B (en) * 2006-06-22 2012-06-20 华为技术有限公司 Charging method for system of putting call through immediately after connection
BRPI1006534B1 (en) * 2009-03-24 2021-05-25 Biocryst Pharmaceuticals, Inc COMPOSITE 1 SALT, PROCESS FOR PREPARING A COMPOSITE 1 SALT, AND PROCESS FOR PREPARING A MIXED COMPOSITE 1 SALT
CL2011000716A1 (en) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Crystalline forms 1 6 of (s) -isopropyl-2 - (((s) - (((2r.3r.4r.5r) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2h) -yl) -4-fluoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate; pharmaceutical composition and combination; and its use to treat a hepatitis c virus infection.
WO2012074912A1 (en) 2010-11-29 2012-06-07 Albert Einstein College Of Medicine Of Yeshiva University Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
US11186575B2 (en) * 2012-08-07 2021-11-30 Alber Einslein College of Medicine Treatment of helicobacter pylori infections
CN111499639B (en) * 2019-01-31 2022-03-04 四川大学华西医院 Pyrimidone derivatives and their use in pharmacy

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4985433A (en) * 1989-10-31 1991-01-15 Biocryst, Inc. 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US4985434A (en) * 1989-10-31 1991-01-15 Biocryst, Inc. 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
US4988702A (en) * 1986-08-26 1991-01-29 Warner-Lambert Company Novel 9-deazaguanines
US5008265A (en) * 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5008270A (en) * 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5061707A (en) * 1986-08-26 1991-10-29 Warner-Lambert Company 9-deazaguanines to treat psoriasis
US5101030A (en) * 1986-08-26 1992-03-31 Warner-Lambert Company 9-deazaguanines
US5102879A (en) * 1986-08-26 1992-04-07 Warner-Lambert Company Method of treating gout with novel 9-deazaguanines
US5189039A (en) * 1989-11-29 1993-02-23 Biocryst, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo[3,2d]pyrimidine and pharmaceutical uses and compositions containing the same
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
US6255314B1 (en) * 1996-09-24 2001-07-03 Taiho Charmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
US7390890B2 (en) * 1997-10-14 2008-06-24 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US7405297B2 (en) * 1999-04-08 2008-07-29 Industrial Research Limited Process for preparing inhibitors of nucleoside metabolism
US20080280334A1 (en) * 2004-06-04 2008-11-13 Dirk Henning Lenz Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds
US7553839B2 (en) * 2002-08-21 2009-06-30 Industrial Research Limited 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US20090233948A1 (en) * 2005-05-20 2009-09-17 Gary Brian Evans Inhibitors of nucleoside phosphorylases and nucleosidases
US20090325986A1 (en) * 2005-12-15 2009-12-31 Richard Hubert Furneaux Deazapurine Analogs of 1'-Aza-L-Nucleosides
US7655795B2 (en) * 2003-02-04 2010-02-02 Industrial Research Limited Process for preparing pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US20100062995A1 (en) * 2006-09-26 2010-03-11 Schramm Vern L Transition state structure of human 5'methylthioadenosine phosphorylase
US20100168141A1 (en) * 2006-12-22 2010-07-01 Gary Brian Evans Azetidine analogues nucleosidase and phosphorylase inhibitors
US20100222370A1 (en) * 2006-02-24 2010-09-02 Schramm Vern L Methods of Treating Cancer
US20110046167A1 (en) * 2006-09-07 2011-02-24 Keith Clinch Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293727C (en) * 1986-08-26 1991-12-31 Catherine Rose Kostlan 9-deazaguanines
WO1991006548A1 (en) * 1989-10-31 1991-05-16 Biocryst, Inc. Inhibitors of purine nucleoside phosphorylase
AU1739097A (en) 1996-02-23 1997-09-10 Albert Einstein College Of Medicine Of Yeshiva University Enzyme detection/assay method and substrates
AU2001284564A1 (en) 2000-08-29 2002-03-13 Albert Einstein College Of Medicine Of Yeshiva University Nucleoside metabolism inhibitors
US6458799B1 (en) 2000-08-31 2002-10-01 Biocryst Pharmaceuticals, Inc. Deazaguanine analog, preparation thereof and use thereof
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US20090012104A1 (en) 2004-07-27 2009-01-08 Babu Yarlagadda S Inhibitors of 5'-Methylthioadenosine Phosphorylase and 5'-Methylthioadenosine/S-Adenosylhomocysteine Nucleosidase
JP2009528996A (en) 2006-02-24 2009-08-13 インダストリアル リサーチ リミテッド Methods for treating diseases using nucleoside phosphorylases and inhibitors of nucleosidases

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4988702A (en) * 1986-08-26 1991-01-29 Warner-Lambert Company Novel 9-deazaguanines
US5061707A (en) * 1986-08-26 1991-10-29 Warner-Lambert Company 9-deazaguanines to treat psoriasis
US5101030A (en) * 1986-08-26 1992-03-31 Warner-Lambert Company 9-deazaguanines
US5102879A (en) * 1986-08-26 1992-04-07 Warner-Lambert Company Method of treating gout with novel 9-deazaguanines
US4985433A (en) * 1989-10-31 1991-01-15 Biocryst, Inc. 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US4985434A (en) * 1989-10-31 1991-01-15 Biocryst, Inc. 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
US5008265A (en) * 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5008270A (en) * 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5189039A (en) * 1989-11-29 1993-02-23 Biocryst, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo[3,2d]pyrimidine and pharmaceutical uses and compositions containing the same
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
US6255314B1 (en) * 1996-09-24 2001-07-03 Taiho Charmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
US7390890B2 (en) * 1997-10-14 2008-06-24 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US7405297B2 (en) * 1999-04-08 2008-07-29 Industrial Research Limited Process for preparing inhibitors of nucleoside metabolism
US7553839B2 (en) * 2002-08-21 2009-06-30 Industrial Research Limited 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US20090239885A1 (en) * 2002-08-21 2009-09-24 Gary Brian Evans Inhibitors of nucleoside phoshorylases and nucleosidases
US7655795B2 (en) * 2003-02-04 2010-02-02 Industrial Research Limited Process for preparing pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US20080280334A1 (en) * 2004-06-04 2008-11-13 Dirk Henning Lenz Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds
US20090233948A1 (en) * 2005-05-20 2009-09-17 Gary Brian Evans Inhibitors of nucleoside phosphorylases and nucleosidases
US20090325986A1 (en) * 2005-12-15 2009-12-31 Richard Hubert Furneaux Deazapurine Analogs of 1'-Aza-L-Nucleosides
US20100222370A1 (en) * 2006-02-24 2010-09-02 Schramm Vern L Methods of Treating Cancer
US20110046167A1 (en) * 2006-09-07 2011-02-24 Keith Clinch Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase
US20100062995A1 (en) * 2006-09-26 2010-03-11 Schramm Vern L Transition state structure of human 5'methylthioadenosine phosphorylase
US20100168141A1 (en) * 2006-12-22 2010-07-01 Gary Brian Evans Azetidine analogues nucleosidase and phosphorylase inhibitors

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239885A1 (en) * 2002-08-21 2009-09-24 Gary Brian Evans Inhibitors of nucleoside phoshorylases and nucleosidases
US8173662B2 (en) 2002-08-21 2012-05-08 Industrial Research Limited Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases
US8183019B2 (en) 2004-06-04 2012-05-22 Industrial Research Limited Method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
US20080280334A1 (en) * 2004-06-04 2008-11-13 Dirk Henning Lenz Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds
US20090233948A1 (en) * 2005-05-20 2009-09-17 Gary Brian Evans Inhibitors of nucleoside phosphorylases and nucleosidases
US20090325986A1 (en) * 2005-12-15 2009-12-31 Richard Hubert Furneaux Deazapurine Analogs of 1'-Aza-L-Nucleosides
US20090227532A1 (en) * 2006-02-22 2009-09-10 Richard Hubert Furneaux Analogues of Coformycin and Their Use for Treating Protozoan Parasite Infections
US8394950B2 (en) 2006-02-22 2013-03-12 Industrial Research Limited Analogues of coformycin and their use for treating protozoan parasite infections
US8916571B2 (en) 2006-02-24 2014-12-23 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating cancer using inhibitors of 5′-methylthioadenosine phosphorylase
US20110092521A1 (en) * 2006-02-24 2011-04-21 Richard Hubert Furneaux Methods of Treating Diseases Using Inhibitors of Nucleoside Phosphorylases and Nucleosidases
US8383636B2 (en) 2006-09-07 2013-02-26 Industrial Research Limited Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase
US20110046167A1 (en) * 2006-09-07 2011-02-24 Keith Clinch Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase
US8853224B2 (en) 2006-09-07 2014-10-07 Industrial Research Limited Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
US8283345B2 (en) 2006-12-22 2012-10-09 Industrial Research Limited Azetidine analogues of nucleosidase and phosphorylase inhibitors
US20100168141A1 (en) * 2006-12-22 2010-07-01 Gary Brian Evans Azetidine analogues nucleosidase and phosphorylase inhibitors
US20110190265A1 (en) * 2008-09-22 2011-08-04 Schramm Vern L Methods and compositions for treating bacterial infections by inhibiting quorum sensing
US9493465B2 (en) 2009-07-17 2016-11-15 Victoria Link Limited 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase
US9957272B2 (en) 2009-07-17 2018-05-01 Victoria Link Limited 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase

Also Published As

Publication number Publication date
JP4806746B2 (en) 2011-11-02
CN100357308C (en) 2007-12-26
PT1590360E (en) 2012-08-27
EP1590360B1 (en) 2012-07-11
RU2334757C2 (en) 2008-09-27
KR101185120B1 (en) 2012-09-21
KR20050114614A (en) 2005-12-06
US20060217551A1 (en) 2006-09-28
ES2391043T3 (en) 2012-11-20
DK1590360T3 (en) 2012-08-27
US7655795B2 (en) 2010-02-02
CA2514992A1 (en) 2004-08-19
CN1771254A (en) 2006-05-10
WO2004069856A1 (en) 2004-08-19
BRPI0407210A (en) 2006-01-24
EP1590360A4 (en) 2009-06-24
SI1590360T1 (en) 2012-11-30
AU2004208968A1 (en) 2004-08-19
CY1113297T1 (en) 2016-04-13
HK1089448A1 (en) 2006-12-01
RU2005127630A (en) 2006-06-27
CA2514992C (en) 2012-08-07
JP2006516615A (en) 2006-07-06
NZ523970A (en) 2005-02-25
EP1590360A1 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
US20100094003A1 (en) Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases
EP1539783B1 (en) Inhibitors of nucleoside phosphorylases and nucleosidases
EP1165564B1 (en) Process for preparing inhibitors of nucleoside metabolism
WO2008030118A1 (en) Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
WO2009082247A1 (en) Process for preparing immucillins having a methylene link
CZ20031209A3 (en) Glycosidation process of indolocarbazole
Castro-Pichel et al. A facile synthesis of ascamycin and related analogues
AU2004208968B2 (en) Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases
Lin et al. Synthesis of a series of purine 2′, 3′-dideoxy-L-nucleoside analogues as potential antiviral agents
Kohda et al. Chemical reactivity of alkylguanines. I. Methylation of O6-methylguanine derivatives
MARUYAMA et al. Synthesis and Physicochemical Properties of 6-O-Cyclopyrimidine Nucleosides
Chung et al. Synthesis of certain [6: 5: 6] linear tricyclic nucleosides as potential antitumor agents
Maruyama et al. Photochemical Synthesis of Phosphonopyrimidine and Phosphonopurine Ribonucleosides
Kojima et al. Nucleosides and Nucleotides. Part 207: Studies in the Chemical Conversion of the 4-Carboxamide Group of 5-Amino-1-β-d-ribofuranosylimidazole-4-carboxamide (AICA-Riboside). Application for the Synthesis of 1-Deazaguanosine
Golankiewicz et al. Synthesis and biological activity of C-acyclic nucleosides of imidazo [1, 5-a]-1, 3, 5-triazines
Padyukova et al. Synthesis of dinucleoside phosphates containing 5'-O-bonded 1-(6-deoxy-β-D-allofuranosyl) uracil and 1-(6-deoxy-α-L-talofuranosyl) uracil
Maruyama et al. Synthesis and Anti-HIV Activity of 2-Substituted 2′-Deoxy-2′-fluoroadenosines
Andrei et al. Stereoselective synthesis of (RP)-8-substituted-N6-acylated and N6-alkylated adenosine-3′, 5′-cyclic phosphorothioic acids as cAMP antagonists
Amer et al. Synthesis of some modified guanosine derivatives
Amer et al. Synthesis of some modified guanosine derivatives
JP2006052182A (en) Method for producing fluorinated purine nucleoside derivative and its intermediate and its production method
EP1816135A1 (en) Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof
SASAKI et al. S kkkk Ph ar m. kk
NZ538368A (en) Inhibitors of nucleoside phosphorylases and nucleosidases

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION